Table 2. Determination of the Antiviral CC50 and IC50 and SI of Nontoxic Doses of Compounds (3a–d, 5a–h, and 6a–h) against SARS-COV-2 VIRUS.
| compound no. | CC50 (μmol) | IC50 (μmol) | SI |
|---|---|---|---|
| 3a | 510.5 | 341.3 | 1.50 |
| 3b | 503.8 | 288.7 | 1.75 |
| 3c | 204.1 | IC50 > CC50 | |
| 3d | 356.0 | IC50 > CC50 | |
| 5a | 356.1 | 126.1 | 2.80 |
| 5b | 349.7 | 151.6 | 2.30 |
| 5c | 432.6 | 287.7 | 1.50 |
| 5d | 428.9 | 168.7 | 2.54 |
| 5e | 344.9 | 86.02 | 4.00 |
| 5f | 467.0 | 77.37 | 6.04 |
| 5g | 483.2 | 106.3 | 4.55 |
| 5h | 303.0 | 92.62 | 3.27 |
| 6a | 415.0 | 47.77 | 8.69 |
| 6b | 314.2 | 45.30 | 6.90 |
| 6c | 434.1 | 73.66 | 5.89 |
| 6d | 468.2 | 49.84 | 9.39 |
| 6e | 467.9 | 18.47 | 25.33 |
| 6f | 360.9 | 15.41 | 23.40 |
| 6g | 416.4 | 34.05 | 12.22 |
| 6h | 180.2 | 30.34 | 5.90 |